

Barnik Invest to Participate in Advanced Therapies Europe 2025 in Barcelona

SOLNA, STOCKHOLM REGION, SWEDEN – August 26, 2025 – Barnik Invest, a leading 360 solution investment partner for Life Science companies, today announced its participation in the Advanced Therapies Europe 2025 conference. The exclusive event, taking place from September 2-4 in Barcelona, will bring together 500 of the most influential minds in cell and gene therapy, including therapeutic developers, pharma leaders, CDMOs, and investors.

The conference is designed to accelerate innovation, investment, and commercialization across the advanced therapies landscape. Barnik Invest will be actively involved in high-impact networking and strategic discussions, seeking new investment opportunities and partnerships.

The event is known for its curated content, including plenary sessions and workshops, as well as exclusive experiences like the Investor Summit, which is tailored for meaningful discussion and strategic alignment. Barnik Invest looks forward to engaging in these focused conversations to find the next wave of therapeutic innovation.

Barnik Invest will be represented at the event by CEO Hamid Bakhshi and COO Sara Nikman, and invites interested parties to reach out via the partnering platform to schedule meetings and explore potential collaboration opportunities.

For more information, please contact;
Hamid Bakhshi, CEO
Telephone: +46738531165
E-mail: info@barnikinvest.com

About Barnik Invest Group

Barnik Invest Group is a leading 360 solution partner for Life Science companies in the Nordics. The company provides a comprehensive suite of services to support its portfolio companies, including capital, clinical development, expertise, and commercialization. Through its fully owned subsidiaries, Medicorent and StartUpPharma, Barnik Invest offers CRO services, outsourcing, recruitment, distribution, product development, and commercialization solutions. Barnik's mission is to nurture promising life science companies from early clinical development to commercialization, enabling them to achieve positive cash flows or successful exits, and ultimately enhancing patient well-being and improving human health worldwide. For more information, visit www.barnikinvest.com.